The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Strijbis EM, Repovic P, Mostert J, Bowen JD, et al. Mult Scler 2022;28:1606-1619.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Strijbis EM, Repovic P, Mostert J, Bowen JD, et al. The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Mult Scler 2022;28:1606-1619.
PMID: 35876467